Skip to search formSkip to main contentSkip to account menu

VEGFR2-targeted Contrast Agent BR55

Known as: BR55 
A lipopeptide-based, vascular endothelial growth factor receptor 2 (VEGRF2) -targeted contrast agent with the property of molecular imaging of… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2013
Review
2013
Liver dysplasia: US molecular imaging with targeted contrast agent enables early assessment.
PURPOSE To investigate the ability of vascular endothelial growth factor receptor type 2 (VEGFR2)-targeted ultrasonographic (US… 
Highly Cited
2011
Highly Cited
2011
Molecular and functional ultrasound imaging in differently aggressive breast cancer xenografts using two novel ultrasound contrast agents (BR55 and BR38)
ObjectivesTo characterise clinically translatable long-circulating (BR38) and VEGFR2-targeted (BR55) microbubbles (MB) and to… 
2001
2001
Influence of cytokines, monoclonal antibodies and chemotherapeutic drugs on epithelial cell adhesion molecule (EpCAM) and LewisY antigen expression
MoAbs against tumour‐associated antigens (TAA) may be useful for the treatment of colorectal cancer. Since an increased… 
Highly Cited
2000
Highly Cited
2000
A Molecular Basis for Functional Peptide Mimicry of a Carbohydrate Antigen*
Peptides may substitute for carbohydrate antigens in carbohydrate-specific immunological reactions. Using the recognition… 
1999
1999
Enhancement of antibody dependent cellular cytotoxicity (ADCC) by combination of cytokines.
Monoclonal antibodies (MAb) specific for tumor-associated antigens (TAA) can induce an immunological cellular attack of tumor… 
Highly Cited
1998
Highly Cited
1998
Antigenic and immunological mimicry of peptide mimotopes of Lewis carbohydrate antigens.
1996
1996
Molecular recognition of the Lewis Y antigen by monoclonal antibodies.
The murine monoclonal antibody BR55-2 is directed against the tumor-associated antigen Lewis Y oligosaccharide. The Lewis Y core… 
1991
1991
Tumor cell lysis and tumor growth inhibition by the isotype variants of MAb BR55-2 directed against Y oligosaccharide.
IgG3 murine MAb BR55-2 is directed against adenocarcinoma associated Y oligosaccharide. Isotype IgG1, IgG2b and IgG2a switch… 
1990
1990
Oligosaccharide Y specific monoclonal antibody and its isotype switch variants.
Isotype switch variants of the IgG3 secreting hybridoma BR55-2 were developed with gamma 1, gamma 2b and gamma 2a heavy chains… 
1989
1989
The tumor-associated antigens BR55-2, GA73-3 and GICA 19-9 in normal and corresponding neoplastic human tissues, especially gastrointestinal tissues.
Immunohistochemical analysis with a monoclonal antibody, anti-BR55-2, was carried out on 163 tumors with their adjacent normal… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)